Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ICUI 
ICU Medical Inc (ICUI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ICUI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $186.2
1 Year Target Price $186.2
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.99% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.33B USD | Price to earnings Ratio - | 1Y Target Price 186.2 |
Price to earnings Ratio - | 1Y Target Price 186.2 | ||
Volume (30-day avg) 6 | Beta 0.89 | 52 Weeks Range 117.92 - 196.26 | Updated Date 07/6/2025 |
52 Weeks Range 117.92 - 196.26 | Updated Date 07/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.87% | Operating Margin (TTM) 4.89% |
Management Effectiveness
Return on Assets (TTM) 1.79% | Return on Equity (TTM) -4.62% |
Valuation
Trailing PE - | Forward PE 20.66 | Enterprise Value 4644162747 | Price to Sales(TTM) 1.38 |
Enterprise Value 4644162747 | Price to Sales(TTM) 1.38 | ||
Enterprise Value to Revenue 1.92 | Enterprise Value to EBITDA 16.67 | Shares Outstanding 24611900 | Shares Floating 23848229 |
Shares Outstanding 24611900 | Shares Floating 23848229 | ||
Percent Insiders 3.04 | Percent Institutions 101.79 |
Upturn AI SWOT
ICU Medical Inc
Company Overview
History and Background
ICU Medical, Inc. was founded in 1984. It has grown through product innovation and strategic acquisitions, becoming a leading provider of infusion therapy and critical care solutions.
Core Business Areas
- Infusion Systems: ICU Medical develops and manufactures infusion pumps, dedicated administration sets, and related software for delivering medications and fluids to patients.
- Medication Delivery: This segment includes products for IV therapy, such as IV sets, connectors, and needlefree devices, designed to enhance patient safety and prevent infections.
- Solutions: Solutions segment provides safety products like closed system transfer devices (CSTD's) for hazardous drugs, and custom solutions that are used for hospitals
Leadership and Structure
Vivek Jain serves as the Chief Executive Officer. The company has a structured organizational framework with functional departments including R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- IV Sets: ICU Medical's IV sets are used for administering intravenous fluids and medications. Competitors include B. Braun and Baxter. Market share is estimated to be around 15-20% in certain segments.
- Infusion Pumps: ICU Medical offers a range of infusion pumps for various clinical settings. Competitors include Becton Dickinson (BD) and Baxter. Market share is estimated to be around 10-15% in certain segments.
- Closed System Transfer Devices (CSTDs): CSTD safety products like ChemoLock provide protection from hazardous drugs for medical professionals. Competitors include Becton Dickinson (BD) and Cardinal Health.
Market Dynamics
Industry Overview
The medical device industry is experiencing steady growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in healthcare. The IV therapy and infusion markets are competitive, with a focus on safety, efficiency, and cost-effectiveness.
Positioning
ICU Medical is positioned as a provider of innovative and reliable infusion therapy solutions. Its competitive advantages include a broad product portfolio, strong customer relationships, and a focus on patient safety.
Total Addressable Market (TAM)
The global infusion therapy market is expected to reach USD 20 billion by 2028. ICU Medical is well-positioned to capture a significant share of this market through its comprehensive product offerings and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Extensive product portfolio
- Focus on patient safety
- Established customer relationships
- Innovative technology
Weaknesses
- Reliance on key customers
- Integration challenges from acquisitions
- Exposure to product liability claims
- Competition from larger players
Opportunities
- Expanding product lines
- Entering new geographic markets
- Developing strategic partnerships
- Capitalizing on industry trends like connected healthcare
Threats
- Intense competition
- Regulatory changes
- Pricing pressures
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- BDX
- BAX
- VTRS
Competitive Landscape
ICU Medical competes with larger medical device companies with broader product portfolios and greater resources. ICU Medicalu2019s focus on infusion therapy and patient safety gives it a competitive edge in specific market segments.
Major Acquisitions
Smiths Medical
- Year: 2022
- Acquisition Price (USD millions): 2350
- Strategic Rationale: The acquisition of Smiths Medical expanded ICU Medical's product portfolio, enhanced its global reach, and created synergies in manufacturing and distribution.
Growth Trajectory and Initiatives
Historical Growth: ICU Medical has historically grown through organic growth and acquisitions.
Future Projections: Analyst estimates vary. Check financial news resources for up-to-date projections.
Recent Initiatives: Recent initiatives include product launches, strategic partnerships, and expansion into new markets.
Summary
ICU Medical is a key player in infusion therapy and critical care. Its strong product portfolio, focus on patient safety, and strategic acquisitions have fueled growth. Intense competition and integration challenges present risks, but continued innovation and market expansion could drive future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ICU Medical Inc
Exchange NASDAQ | Headquaters San Clemente, CA, United States | ||
IPO Launch date 1992-03-31 | CEO & Chairman of the Board Mr. Vivek Jain | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 15000 | Website https://www.icumed.com |
Full time employees 15000 | Website https://www.icumed.com | ||
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. It offers infusion therapy products, such as needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.